恩替卡韦对失代偿期乙型肝炎肝硬化的疗效观察  

Efficiency of entecavir in treatment of decompensate cirrhosis

作　　者：向洪涛[1] 王煜[2] 刘娅[2] 张爱芸[2] 孙燕燕[1] 祁文月[1] 

机构地区：[1]宁夏医科大学,银川750004 [2]宁夏医科大学附属医院感染疾病科

出　　处：《中国实用医刊》2010年第11期12-13,共3页Chinese Journal of Practical Medicine

摘　　要：目的 探讨恩替卡韦对乙型肝炎(以下简称乙肝)肝硬化失代偿期的疗效.方法 将52例乙肝肝硬化失代偿期患者分为两组:对照组25例,在一般综合治疗的基础上给予阿德福韦酯治疗;治疗组27例,在一般综合治疗的基础上给予恩替卡韦治疗.疗程均为12周,观察两组患者治疗前后HBV-DNA定量水平、肝功能、凝血机制(PTA)、腹水、临床症状及体征变化情况.结果 在肝功能和凝血酶原活动度(PTA)恢复方面两组比较差异无统计学意义(P>0.05),在肝功能、PTA、症状体征缓解所需时间方面,两组比较差异有统计学意义(P<0.05),在HBV-DNA水平控制方面,治疗组疗效优于对照组,差异有统计学意义(P<0.05).结论 恩替卡韦抗病毒作用强,可快速抑制乙肝肝硬化失代偿期患者的HBV-DNA复制,降低血清中HBV-DNA水平,从而改善患者肝功能及凝血机制,阻止病情发展,提高生存质量,延长患者生存期.Objective To investigate the effect of entecavir for curing hepatitis B cirrhosis.Methods Fifty-two hepatitis B cirrhosis patients were divided into two groups,25 cases in control group, which added adefovir dipivoxil beyond the basisc treatment, 27 cases in treatment group, which added entecavir on the basic treatment. Two groups had the same course of treatment for 12 weeks. Observing comparison before and after treatment, used HBV-DNA quantitative levels, liver function, blood clotting mechanisms (PTA), ascites, clinical symptoms and signs of change as observation indications.Results There was no significant difference between the two groups in the recovery of liver function or PTA (P>0.05). The differences of liver function, PTA, the time required to alleviate symptoms and signs (T) were significant between the two groups(P<0.05). In the HBV-DNA level of control, the treatment group was better, and the difference was significant (P<0.05).Conclusions Entecavir have a strong antiviruses, it has a quick suppression of HBV-DNA replication and serum HBV-DNA level among hepatitis B patients.Therefore,it can improve liver function and blood clotting mechanism, preventing disease progression, improving quality of life,and prolong survival.

关 键 词：恩替卡韦 阿德福韦酯 乙肝肝硬化失代偿期 

分 类 号：R512.62[医药卫生—内科学]